Glenmark rises on launching Sitagliptin and its FDCs for adults with Type 2 Diabetes in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 389.45, up by 0.55 points or 0.14% from its previous closing of Rs. 388.90 on the BSE.
The scrip opened at Rs. 389.00 and has touched a high and low of Rs. 393.75 and Rs. 388.80 respectively. So far 7361 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 397.00 and Rs. 378.65 respectively. The current market cap of the company is Rs. 10989.04 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 35.08% and 18.27% respectively.
Glenmark Pharmaceuticals has launched sitagliptin and its Fixed Dose Combinations (FDCs), at affordable price for adults with Type 2 diabetes in India. The company has introduced 8 different combinations of sitagliptin based drugs under the brand name SITAZIT and its variants at affordable price.
Glenmark’s SITAZIT and its variants will play an instrumental role in raising accessibility of sitagliptin to type-2 diabetic patients, which is considered as the gold standard molecule in DPP4 inhibitor therapy. It will help the patients to manage their glycemic level effectively and bring better compliance. These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
